March 27, 2017
Bioventix’s increases profit in second half of 2016
Bioventix, a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, has reported unaudited interim financial results for the six-month period ending 31 December 2016.